• AT13387: Advanced Hsp90 Inhibitor for Apoptosis Pathway Diss

  2026-06-09

  Explore how AT13387, a potent Hsp90 inhibitor, enables precise dissection of apoptosis and cell cycle arrest in cancer biology research. This article delivers unique, assay-focused insights for leveraging AT13387 in the context of regulated cell death and recent discoveries on membrane rupture.

• Phosphoproteomic Remodeling in RCC Under Chronic Cabozantini

  2026-06-09

  This study delineates how acute and chronic Cabozantinib (XL184) exposure differentially remodels phosphorylation signaling networks in renal cell carcinoma cells. Quantitative phosphoproteomics reveal that chronic treatment sustains MET inhibition but induces selective adaptation in adhesion- and stress-associated pathways, with functional implications for cell motility and potential resistance mechanisms.

• EPI-001: Androgen Receptor N-Terminal Domain Inhibitor in Ca

  2026-06-08

  EPI-001 uniquely targets the N-terminal domain of androgen receptors, enabling robust inhibition of both full-length and resistant AR variants in prostate and triple-negative breast cancer models. Its use supports advanced workflows for dissecting AR-driven transcriptional activity and metastasis, with protocol-ready guidance for maximizing reproducibility.

• Novel ATG9A and PTOV1–14-3-3 Interactions in Cancer Regulati

  2026-06-08

  This study uncovers ATG9A and PTOV1 as novel 14-3-3 binding proteins, elucidating their roles in autophagy and oncogenic signaling. The findings reveal new mechanistic insights into basal autophagy and PTOV1-mediated cancer progression, offering avenues for targeted therapeutic strategies.

• Forskolin: Adenylate Cyclase Activator for Cell Assays & Reg

  2026-06-07

  Forskolin stands out as a precise adenylate cyclase activator, powering advanced cell-based assays and regenerative workflows. This guide translates state-of-the-art research into actionable protocols, revealing how Forskolin accelerates progenitor cell expansion, fine-tunes cAMP signaling, and overcomes practical bottlenecks in stem cell and disease modeling.

• Dual-Action Kinase Inhibitors Promote p38α MAPK Dephosphoryl

  2026-06-06

  The referenced study uncovers how certain kinase inhibitors, including those structurally related to Imatinib hydrochloride, facilitate p38α MAP kinase dephosphorylation by stabilizing a phosphatase-accessible activation loop conformation. This dual-action mechanism suggests new strategies for improving specificity and potency in tyrosine kinase inhibitor design, with significant implications for cancer research workflows.

• Cholecystokinin Octapeptide Ammonium (SKU C8717): Reliable L

  2026-06-05

  This evidence-driven article addresses common laboratory challenges in cell viability, apoptosis, and neurobehavioral assays by showcasing how Cholecystokinin octapeptide ammonium (SKU C8717) ensures data reliability and practical workflow improvements. Researchers will gain scenario-based guidance rooted in quantitative findings, with actionable insights for assay optimization and protocol design.

• Hydrocortisone for Glucocorticoid Hormone Research: Protocol

  2026-06-05

  Hydrocortisone (APExBIO, SKU B1951) is the gold-standard glucocorticoid hormone for dissecting anti-inflammatory and stress response pathways in advanced cell and animal models. This guide delivers expert-driven workflows, troubleshooting strategies, and actionable insights to optimize your inflammation model research and neuroprotection assays.

• Perifosine (KRX-0401): Translating Akt Pathway Science to St

  2026-06-04

  This thought-leadership article explores the mechanistic and translational significance of Perifosine (KRX-0401) as a synthetic alkylphospholipid Akt inhibitor. It bridges emerging research on apoptosis, Akt/mTOR pathway modulation, and radiation sensitization with actionable guidance for researchers pursuing preclinical and translational studies in cancer and neuroprotection. By integrating reference findings and competitive insights, the article positions Perifosine as a versatile, validated tool enabling innovative experimental design beyond the scope of standard product pages.

• KU-60019: ATM Kinase Inhibitor for Radiosensitizing Glioma M

  2026-06-04

  KU-60019 redefines DNA damage response research by enabling precise ATM kinase inhibition, facilitating potent radiosensitization and migration blockade in glioma models. This guide translates advanced findings into reproducible protocols and troubleshooting strategies, empowering cancer researchers to maximize assay robustness with APExBIO’s trusted compound.

• Pam3CSK4 TFA: Precision TLR1/2 Agonist for Innate Immunity A

  2026-06-03

  Pam3CSK4 TFA is a rigorously validated TLR1/2 agonist that enables high-fidelity modeling of innate immune responses, especially in translational workflows targeting maternal-neonatal immunity and inflammatory risk stratification. Its robust solubility and purity profile, provided by APExBIO, empower reproducible cytokine profiling and mechanistic studies in both in vitro and in vivo contexts.

• Tetrandrine Alkaloid: Applied Protocols for Ion Channel Modu

  2026-06-03

  Tetrandrine stands apart as a high-purity, DMSO-soluble alkaloid engineered for robust ion channel modulation and cell signaling workflows. This guide unpacks practical assay designs, advanced use-cases, and troubleshooting strategies—anchored by the latest cross-domain research and APExBIO’s trusted supply.

• Perospirone Inhibits Vascular Kv1.5 Channels: Implications f

  2026-06-02

  A recent study demonstrates that Perospirone, an atypical antipsychotic, directly inhibits vascular Kv1.5 potassium channels in coronary arterial smooth muscle cells independently of its classical receptor targets. These findings have important implications for both schizophrenia research and cardiovascular safety assessments when using Perospirone in experimental models.

• Catalpol in Translational Disease Models: Protocols & Pitfal

  2026-06-02

  Catalpol, a multi-target iridoid glycoside, enables advanced neuroprotection and disease modeling by modulating key pathways such as VEGF-PI3K/AKT. This article delivers actionable workflows, troubleshooting strategies, and evidence-driven insights for optimizing Catalpol-based protocols across neuroprotection, osteoporosis, ischemic stroke, and liver fibrosis research.

• Lipid Scrambling by TMEM16F Regulates Ferroptosis and Tumor

  2026-06-01

  Yang et al. reveal that TMEM16F-mediated lipid scrambling functions as a key suppressor in the execution phase of ferroptosis by remodeling plasma membrane phospholipids. Disruption of this process enhances ferroptotic cell death and potentiates antitumor immune responses, suggesting new avenues for targeted cancer therapies.

16316 records 1/1088 page Next 12345 下5页 Last page